JNJ JOHNSON & JOHNSON
What matters nowUpdated 3 h ago
- Johnson & Johnson reported third-quarter 2026 worldwide sales of $25.4 billion on 13 October, up 5.9%, with adjusted EPS of $2.59, down 7.5%; reported EPS was $0.09 after a one-time special charge for the proposed talc resolution and the Firefly Bio and Sail deals 1.
- The company raised its reported 2026 sales outlook to $101.0-101.4 billion, while adjusted EPS guidance is $11.05-11.15 after about $0.64 of 2026 dilution from those two deals 1.
- The pooled 24/7 venue price of JNJ was $248.51 on 13 October, down 5.9% from $264.02; the 5.72% fall that day is the largest of the last five recorded moves and came on the day of the results 1.
- Trailing twelve-month revenue is $97.9 billion, up 8.1% year on year, with TTM EPS of $8.62 (down 7.8%), a 21.5% net margin and a P/E of 28.8 on a $598.8 billion market cap (fundamentals as of 28 June 2026); insiders sold 269,340 shares worth $70.2 million over 180 days and made no buys.
- ICOTYDE received European Commission approval on 21 September 2026 for moderate-to-severe plaque psoriasis 2, and two-year ICONIC-TOTAL data showed 70% of patients at clear or almost clear skin at week 112 3; the Q4 and full-year 2026 results and investor call are confirmed for 26 January 2027.
- Polymarket gives an 81.5% chance of no Fed rate change after the October 2026 meeting, and the September CPI release is due on 14 October 2026.
Johnson & Johnson 8-K (SEC) · Oct 13
Johnson & Johnson press release · Sep 21
Johnson & Johnson press release · Oct 2
Valuation & fundamentalsFull financials →
TTM through 2026-06-28 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| okx perp JNJ-USDT-SWAP · just now | 248.96 | +0.08% | $269.5K | $120.1K | 0.0000% |
| bybit perp JNJUSDT · just now | 248.78 | 0.00% | $221.3K | $109.9K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
J&J Q3 2026 sales rise 5.9% to $25.4B; raises reported sales guidance
Johnson & Johnson reported third-quarter 2026 worldwide sales of $25.4 billion, up 5.9%, and adjusted EPS of $2.59, down 7.5%.
J&J declares $1.34 quarterly dividend for fourth quarter 2026
The Board of Directors declared a cash dividend of $1.34 per share for the fourth quarter of 2026, announced alongside the third-quarter results.
ICOTYDE two-year ICONIC-TOTAL data show 70% clear or almost clear skin
J&J presented two-year Phase 3 ICONIC-TOTAL data for ICOTYDE at the EADV Congress 2026 as a late-breaking oral presentation.
European Commission approves ICOTYDE for moderate-to-severe plaque psoriasis
The European Commission granted marketing authorisation to ICOTYDE (icotrokinra), an oral IL-23 receptor blocker, for adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy.
J&J schedules Q3 2026 results and investor call for October 13
Johnson & Johnson announced that it will release third-quarter 2026 results around 6:45 a.m.
FDA approves IMAAVY as first treatment for warm autoimmune hemolytic anemia
The FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia in adults and in patients aged 12 and older who have received corticosteroids.
Jennifer Taubert to retire; Tom Cavanaugh named head of Innovative Medicine
Johnson & Johnson said Executive Vice President Jennifer Taubert will retire after more than 21 years, and Tom Cavanaugh will succeed her as Executive Vice President and Worldwide Chairman of Innovative Medicine.
FDA grants Priority Review to RYBREVANT FASPRO in head and neck cancer
The FDA granted Priority Review to the supplemental application for subcutaneous RYBREVANT FASPRO in recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and a PD-1 or PD-L1 inhibitor.
J&J completes $1 billion cash acquisition of Firefly Bio
Johnson & Johnson completed its acquisition of Firefly Bio for $1 billion in cash.
J&J takes equity stake in Sail Biomedicines with option to buy for $2.58 billion
J&J announced a collaboration with Sail Biomedicines, a Flagship Pioneering company developing in vivo CAR-T therapies for immune-mediated diseases.
J&J proposes at least $5.5 billion deal to resolve ovarian talc litigation
Johnson & Johnson proposed a comprehensive resolution of ovarian talc litigation covering about 76,000 lawsuits, with a commitment of at least $5.5 billion paid per claim.
TECVAYLI plus TALVEY cuts progression or death risk 89% in Phase 3 MonumenTAL-6
Phase 3 MonumenTAL-6 met its primary endpoint in earlier-line relapsed or refractory multiple myeloma.
FDA grants De Novo authorization to J&J's OTTAVA surgical robot
The FDA granted De Novo marketing authorization to the OTTAVA Robotic Surgical System for upper-abdominal general surgery, including gastric bypass, gastrectomy, gallbladder removal, gastric sleeve and hiatal hernia repair.
J&J beats Q2 2026 estimates and raises full-year sales and EPS outlook
Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.3 billion, up 6.6% reported, and adjusted EPS of $2.90, up 4.7%.
J&J declares $1.34 quarterly dividend for third quarter 2026
The Board of Directors declared a cash dividend of $1.34 per share for the third quarter of 2026, unchanged from the prior quarter.